He later admitted to using the blood-booster EPO, and received a one-year suspension Nov. 16.
As with the EPO-2 study, a survival benefit was identified in critically ill trauma patients who received EPO: at day 29 (deaths: placebo 6.7% vs. EPO 3.5%), day 42 (deaths: placebo 7.2% vs. EPO 3.7%), and day 140 (deaths: placebo 9.2% vs. EPO 6.0%).
CD34+KDR+-EPC tended to be lower in patients without EPO therapy after 52 weeks compared to those who received EPO therapy (p=0.077), whereas levels were not different between the groups at baseline (p=0.437).
Of note, the incidence of adverse cardiovascular events including death was significantly higher in patients who received EPO in that study, raising alarm against the use of higher doses of EPO.
Patients received EPO treatment (50 IU/kg/week; Neorecormon, Roche Pharmaceuticals, Woerden, Netherlands) or standard treatment without EPO for one year.
Patients had not received EPO previously.
Subgroup analysis, however, showed that severe long-term neurological deficit (that is, long-term Barthel Index <35) was substantially lower in patients who had received EPO therapy than in the placebo-control group.
When participants (n=18) received recombinant EPO injections (50 IU/kg 3×/week) for a period of 25 d, they increased more proportionately with the increase in Hbmass (r=0.28) when compared with the current data set, 39 adding support to this apparent uncoupling of the Hbmass– relationship with altitude training.
Mice were then randomized to receive EPO- α (400 units/kg/day/sc) or EPO-Z (400 units/kg/day/sc) or their vehicle (100 μL/day/sc 0.9% NaCl solution).
Animals in the radiolabeled portion of the study were divided into cohorts of 18 who either received 125I-EPO or 125I-Calcitonin.
Septic mice in three experiments received rHu-EPO 400 U/kg subcutaneously 18 hours after cecal ligation and perforation (CLP).
